Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;62(2):311-329.
doi: 10.1002/bimj.201800390. Epub 2019 Sep 25.

Adjusting Simon's optimal two-stage design for heterogeneous populations based on stratification or using historical controls

Affiliations

Adjusting Simon's optimal two-stage design for heterogeneous populations based on stratification or using historical controls

Dominic Edelmann et al. Biom J. 2020 Mar.

Abstract

In many cancer studies, the population under consideration is highly heterogeneous in terms of clinical, demographical, and biological covariates. As the covariates substantially impact the individual prognosis, the response probabilities of patients entering the study may strongly vary. In this case, the operating characteristics of classical clinical trial designs heavily depend on the covariates of patients entering the study. Notably, both type I and type II errors can be much higher than specified. In this paper, two modifications of Simon's optimal two-stage design correcting for heterogeneous populations are derived. The first modification assumes that the patient population is divided into a finite number of subgroups, where each subgroup has a different response probability. The second approach uses a logistic regression model based on historical controls to estimate the response probabilities of patients entering the study. The performance of both approaches is demonstrated using simulation examples.

Keywords: adaptive design; clinical trial; heterogeneous population; historical control; stratified design.

PubMed Disclaimer

References

REFERENCES

    1. Barnes, C. N., & Rai, S. N. (2010). The effects of heterogeneity on Simon phase II clinical trial design operating characteristics. Open Access Journal of Clinical Trials, 2, 107-114.
    1. Chang, M. N., Shuster, J. J., & Hou, W. (2012). Improved two-stage tests for stratified phase II cancer clinical trials. Statistics in Medicine, 31, 1688-1698.
    1. Chen, S. X., & Liu, J. S. (1997). Statistical applications of the Poisson-binomial and conditional Bernoulli distributions. Statistica Sinica, 7, 875-892.
    1. Cook, T. D., & DeMets, D. L. (Eds.). (2007). Introduction to statistical methods for clinical trials. London: Chapman and Hall.
    1. Jung, S.-H., Chang, M. N., & Kang, S. J. (2012). Phase II cancer clinical trials with heterogeneous patient populations. Journal of Biopharmaceutical Statistics, 22, 312-328.

LinkOut - more resources